Volume No. :   5

Issue No. :  1

Year :  2013

ISSN Print :  0975-4407

ISSN Online :  2321-5836


Registration

Allready Registrered
Click to Login

Post Stent Implantation Effect of Antiplatelet



Address:   Jatin Patel*
PhD Research Scholar, Department of Pharmacy, JJT University, Vidyanagari, Churu Jhunjhunu Road, Chudela, District-Jhunjhunu– 333001, Rajasthan, India
*Corresponding Author
DOI No: Not Available

ABSTRACT:
Here we found a clustering of death and MI events in the initial 90-day period after clopidogrel cessation, compared with subsequent follow-up intervals. Findings were consistent among subgroups of patients who received shorter or longer durations of clopidogrel therapy, patients with or without diabetes, and ACS patients who underwent PCI. The rate of adverse events in the initial 90-day interval after stopping clopidogrel was higher than the rate of adverse events following hospital discharge while patients were still taking clopidogrel. These findings support the hypothesis of a rebound hyperthrombotic period after clopidogrel cessation. They also highlight the need for additional studies to confirm these findings and to gain a deeper understanding of the pathophysiology of this phenomenon as well as allowing identification of strategies to attenuate this effect. Clopidogrel keeps the platelets in your blood from coagulating (clotting) to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions. Clopidogrel is used to prevent blood clots after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels. We observed a clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI-treated patients with ACS, supporting the possibility of a clopidogrel rebound effect
KEYWORDS:
PCI (percutaneous coronary intervention) ,ACS (acute coronary syndrome), Clopidogrel, MI (myocardial infraction)
Cite:
Jatin Patel . Post Stent Implantation Effect of Antiplatelet . Research J. Pharmacology and Pharmacodynamics. 2013; 5(1): 26-36.
[View HTML]      [View PDF]



Visitor's No. :   124375